NeoGenomics, Inc.
NASDAQ: NEO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Anthony Zook
- Employees
- 2,200
- Headquarters
- Fort Myers, United States
- IPO year
- 2004
- Market cap
- $335.9M
- Website
- https://www.neogenomics.com
Loading NEO…
Loading profile data…Frequently asked questions about NEO
What does NeoGenomics, Inc. (NEO) do?
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including...
Where does NEO trade?
NeoGenomics, Inc. (NEO) trades on the NASDAQ Capital Market.
What sector is NEO in?
NeoGenomics, Inc. (NEO) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of NeoGenomics, Inc.?
Anthony Zook is the chief executive officer of NeoGenomics, Inc. (NEO).
Where is NeoGenomics, Inc. headquartered?
NeoGenomics, Inc. is headquartered in United States.
Does NEO pay a dividend?
NeoGenomics, Inc. (NEO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NEO go public?
NeoGenomics, Inc. (NEO) completed its initial public offering in 2004.
Is NEO an ADR?
Yes — NEO is an American Depositary Receipt; its underlying shares trade on a non-US exchange. NeoGenomics, Inc. reporting and dividends follow the underlying issuer.